188P - The impact of Oncotype DX breast cancer assay results on clinical practice – a UK experience

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Breast Cancer, Early Stage
Breast Cancer
Personalised Medicine
Presenter Valerie Crolley
Citation Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362
Authors V.E. Crolley1, H. Marashi2, S.K.R. Rawther3, M. Parton4, J. Graham5, A. Vinayan6, S. Sutherland7, A. Rigg8, A. Wadhawan9, C. Harper-Wynne10, E. Spurrell11, H. Bond12, F. Raja13, J. King14
  • 1Oncology, Royal Free Hospital, NW3 2QG - London/GB
  • 2Oncology, Beatson West of Scotland Cancer Centre, Glasgow/GB
  • 3Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield/GB
  • 4Oncology, Royal Marsden NHS Foundation Hospital, London/GB
  • 5Oncology, South Tees NHS Foundation Trust, Northallerton/GB
  • 6Oncology, East And North Hertfordshire NHS Trust, Stevenage/GB
  • 7Oncology, Mount Vernon Cancer Centre, London/GB
  • 8Oncology, Guys and St Thomas NHS Foundation Trust, London/GB
  • 9Oncology, Velindre NHS Trust, Cardiff/GB
  • 10Oncology, Maidstone and Tunbridge Wells NHS Trust, Maidstone/GB
  • 11Oncology, The Whittington Hospital NHS Trust, London/GB
  • 12Oncology, Royal Cornwall Hospitals NHS Trust, Truro/GB
  • 13Oncology, University College London Hospitals NHS Foundation Trust, London/GB
  • 14Medical Oncology, Royal Free Hospital, London, NW3 2QG - London/GB

Abstract

Background

Gene expression profiling is increasingly being used by clinicians to help determine whether or not to offer adjuvant chemotherapy. Oncotype DX is a 21 gene panel developed to predict the risk of tumour recurrence in patients with oestrogen receptor (ER) positive, HER2 negative breast cancer. NICE has recommended its use for patients at intermediate risk of recurrence, where this information would help clinicians to assess the potential benefit of chemotherapy versus endocrine therapy alone. Our aim was to see how oncologists are interpreting Oncotype DX tests in their clinical practice.

Methods

Data on patient and tumour characteristics (size, grade, ER/PR/HER2/nodal status), Oncotype DX recurrence score, treatment options offered and treatment outcomes were collected from 14 cancer centres across the UK.

Results

Of the 628 patients tested, 317 (50%) were in the low risk category (recurrence score

Conclusions

Throughout the UK, about half of patients tested had low risk Oncotype scores and the majority (74.1%) of patients tested did not receive chemotherapy. The widest variation in clinical practice was observed in interpreting intermediate risk Oncotype results, and in the chemotherapy regimens offered.

Clinical trial identification

Legal entity responsible for the study

Judy King

Funding

None

Disclosure

All authors have declared no conflicts of interest.